There are existing approaches, including the introduction of epigenetic modifying agents into leukaemia treatment protocols33, and PLA2R1 promoter methylation may be an indicator to predict the effectiveness of such treatment strategies19. The gene discussed is PLA2R1; the disease is leukemia.